close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

2.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Recap: Repare Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Why RingCentral Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're diving into the biggest pre-market stock movers for Wednesday will a look at all of the latest news happening this morning. 
Via InvestorPlace
News headline image
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
RPTX stock results show that Repare Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
From Debiopharm
Via Business Wire
News headline image
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients ↗
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. 
Via Benzinga
News headline image
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
From Kirby McInerney LLP
Via Business Wire
News headline image
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
From Repare Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today